Navigation Links
Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
Date:9/11/2008

MONTVALE, N.J., Sept. 11 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) today announced findings from a study that indicated Synvista's proprietary monoclonal enzyme immunoassay can determine a person's haptoglobin pheno/genotype in less than two hours, and can aid physicians in predicting cardiovascular risk in patients with diabetes. The study was presented today at the 2008 Cardiovascular Biomarkers and Surrogate Endpoints Symposium in Bethesda, Maryland.

"This study shows the utility of our proprietary technology to diagnose Hp2-2 Diabetes, a disease affecting almost 7 million people in the United States," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics. "We believe that the ease of use of our haptoglobin diagnostic technology and rapid results bode well for its acceptance as an important tool in the treatment of cardiovascular disease in diabetic patients. In addition, we believe that the development of genetic markers like those identified by our test will continue to pave the way toward a personalized medicine model that will benefit a wider variety of patients in a more direct and reliably predictive manner."

In the study, investigators developed an ELISA (enzyme-linked immunosorbent assay) using a monoclonal antibody that differentiates between the three haptoglobin pheno/genotypes. Blood samples from diabetic patients with known haptoglobin pheno/genotypes were tested using Synvista's proprietary methodology. Results demonstrated 99.5% accuracy in determining each of the three haptoglobin types (48/48 Hp 1-1, 49/49 Hp2-1 and 90/91 Hp-2-2) with a greater than or equal to 98% sensitivity and specificity for each phenotype.

Additionally, a secon
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
2. Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
3. Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
4. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
5. New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
6. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
7. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
8. Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
9. Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer
10. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
11. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  VentiRx Pharmaceuticals, Inc., a ... development and commercialization of novel Toll-like receptor ... U.S. Food and Drug Administration (FDA) has ... of motolimod (VTX-2337) when administered in combination ... treatment of women with ovarian cancer whose ...
(Date:9/2/2014)... , Sept. 2, 2014 Bluegrass ... company focused on innovating lifesaving devices and methods ... of Dr. Gabriele Niederauer , a seasoned ... Following the recent closure of Series A financing, ... the Surfacer™ Inside-Out Access Catheter System, a proprietary ...
(Date:9/2/2014)... LAUSANNE , Switzerland , ... after receiving ISO 13485 accreditation, Sophia Genetics has become ... mark for the clinical use of a Next Generation Sequencing ... assurance certification represents an important step in raising ... diagnosis, and brings Sophia Genetics, world-leading Data Driven ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO 2Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing 2
... 20 The District of Columbia Patients, Cooperative ... the District of Columbia, has submitted comments to the ... on proposed regulations announced 45 days ago.   ... http://www.dcpatients.org/DCPC_comments.pdf along with the comments of cannabis ...
... NewBridge Pharmaceuticals FZ-LLC of Dubai, UAE announced today that ... Executive Officer and a member of the company,s Board ... joins NewBridge after a career extending over 29 years ... positions covering many geographies including; US, Europe, and Middle ...
Cached Medicine Technology:DC Patients' Cooperative Urges Changes to the Proposed Medical Cannabis 'Marijuana' Regulations 2NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments 2NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments 3
(Date:9/2/2014)... September 02, 2014 As an industry transformation ... an industry and predict change. Fortunately for him, that valuable ... to identify markets that are eager for change — such ... the hearing aid market indicated it was ripe for better ... Sapio explained. As a result, he took matters into his ...
(Date:9/2/2014)... available in Spanish . ... through an experiment conducted on rats, that hyperproteic diets could ... for groups with bone disease problems, such as the elderly ... vegetal proteinin the case of the present study, soy proteinis ... former increased the level of calcium in bones by as ...
(Date:9/2/2014)... in their work care for patients who are dying. ... that many nurses in training feel unprepared and anxious ... end-of-life care. , Scientists from the Sahlgrenska Academy have ... the University of Skvde and the Ersta Skndal University ... for dying patients, their ideas about how to support ...
(Date:9/2/2014)... 2014 Catalent, the leading global ... for drugs, biologics and consumer health products, today ... Eli Lilly’s growth, it is to install new ... Philadelphia Clinical Supply Center of Excellence. , Catalent ... its clinical supply facility in Schorndorf, Germany, providing ...
(Date:9/2/2014)... 02, 2014 Splashtop Inc. , ... partnership with NTT DoCoMo to deliver Splashtop ... Splashtop Business Lite is included in NTT DoCoMo’s “Business ... desktop software that empower users to remote access their ... garnered over 18 million users worldwide. Splashtop delivers ...
Breaking Medicine News(10 mins):Health News:David Sapio Launches Zounds Hearing Franchise 2Health News:Study conducted on rats suggests that hyperproteic diets can be beneficial for bones 2Health News:Many nurses unprepared to meet dying patients 2Health News:Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions 2Health News:Splashtop and NTT DoCoMo Partner to Deliver “Splashtop Business Lite” Secure Remote Access Solution to Business Customers 2
... discovery in a Florida State University College of Medicine ... to one day help scientists learn how to stop ... are forming. , Jamila Horabin, associate professor of biomedical ... four-year, $1.2 million grant from the National Institutes of ...
... develop a custom solution for The Kidney Foundation of Canada that will ... ... (Vocus) January 9, 2009 -- Blackbaud, Inc. (Nasdaq: BLKB ) today ... of Canada that will create a unified national CRM and web presence., ...
... (PHILADELPHIA) Efforts to fight the toll of cardiac ... CPR education and improvement, public defibrillation programs, and quicker ... Pennsylvania School of Medicine reveals that the hospital where ... key role in their chances of survival following these ...
... Both a Membership Card and Debit Card for Health-related ExpensesPITTSBURGH, ... inconvenience often associated with a Flexible Spending Account (FSA) with ... card - which is unique to Western Pennsylvania - serves ... a debit card for out-of-pocket health care expenses.The My ...
... More than 1,800 in Florida Alone ST. PETERSBURG, Fla., ... franchise, announced today the launch of its low-cost, home-based ... consumers containing their comprehensive medical history. eMed-ID is ... medical history on an easy-to-carry or wearable USB device. ...
... to tomorrow,s (and even today,s) health problems may be ... 2009 Consumer Electronics ShowLAS VEGAS, Jan. 9 ... technology changing the way we shop, listen to music, ... family. However, managing an illness or disability remains a ...
Cached Medicine News:Health News:Researcher wins $1.2 million grant for gene regulation work 2Health News:Blackbaud to Deliver National CRM Database and Bilingual Website for The Kidney Foundation of Canada 2Health News:Blackbaud to Deliver National CRM Database and Bilingual Website for The Kidney Foundation of Canada 3Health News:Blackbaud to Deliver National CRM Database and Bilingual Website for The Kidney Foundation of Canada 4Health News:Penn study: Chances of surviving cardiac arrest depend on where patients are treated 2Health News:Penn study: Chances of surviving cardiac arrest depend on where patients are treated 3Health News:UPMC Health Plan Introduces `MyFlex Advantage' Card 2Health News:UPMC Health Plan Introduces `MyFlex Advantage' Card 3Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 2Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 3Health News:Meridian Makes CES Good For Your Health 2
... The dual lumen ... a 1.2 mm inner ... ,Dual oval lumen catheters ... while maintaining maximum catheter ...
The mid-sized titanium port is about 3/4 the diameter and half the weight of the standard model. The silicone catheter has an I.D. of 1.0 mm....
The WaveMap provides immediate clinical decision making information with automatic calculation of pressure gradients and FFR measurements.,SmartWire Pressure Guide Wire - The intelligent choice in ...
... Used for vascular access. ... facilitates single wall puncture with ... sideport is visualized while maintaining ... Sideport exits the hub of ...
Medicine Products: